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The glycan CA19-9 promotes
pancreatitis and pancreatic
cancer in mice
Dannielle D. Engle1,2*, Hervé Tiriac1,2†, Keith D. Rivera1, Arnaud Pommier1,2‡,
Sean Whalen3, Tobiloba E. Oni1,2, Brinda Alagesan1,2, Eun Jung Lee1,2,
Melissa A. Yao1,2, Matthew S. Lucito1,2, Benjamin Spielman1,2, Brandon Da Silva1,2,
Christina Schoepfer1,2, Kevin Wright1,2, Brianna Creighton1,2, Lauren Afinowicz1,2,
Kenneth H. Yu4,5, Robert Grützmann6, Daniela Aust7, Phyllis A. Gimotty8,
Katherine S. Pollard3,9, Ralph H. Hruban10, Michael G. Goggins10,11,
Christian Pilarsky6, Youngkyu Park1,2, Darryl J. Pappin1,
Michael A. Hollingsworth12, David A. Tuveson1,2§
Glycosylation alterations are indicative of tissue inflammation and neoplasia, but whether
these alterations contribute to disease pathogenesis is largely unknown.To study the role of
glycan changes in pancreatic disease,we inducibly expressed human fucosyltransferase 3 and
b1,3-galactosyltransferase 5 in mice, reconstituting the glycan sialyl-Lewisa, also known
as carbohydrate antigen 19-9 (CA19-9). Notably, CA19-9 expression in mice resulted in rapid
and severe pancreatitis with hyperactivation of epidermal growth factor receptor (EGFR)
signaling. Mechanistically, CA19-9modification of thematricellular protein fibulin-3 increased
its interactionwith EGFR, and blockade of fibulin-3, EGFR ligands, or CA19-9 prevented EGFR
hyperactivation in organoids. CA19-9–mediated pancreatitis was reversible and could be
suppressed with CA19-9 antibodies. CA19-9 also cooperated with the KrasG12D oncogene to
produce aggressive pancreatic cancer. These findings implicate CA19-9 in the etiology of
pancreatitis and pancreatic cancer and nominate CA19-9 as a therapeutic target.
P
ancreatitis, or inflammation of the pan-
creas, is a painful, recurrent, and occasion-
ally lethal medical disorder with limited
treatment options. The incidence of acute
and chronic pancreatitis is rising (1). Pan-
creatitis accounts for more than 275,000 hospi-
talizations in the United States per year, and the
number of hospital admissions has increased
by 20% over the past decade (2). The causes of
pancreatitis include blockage of the pancreatic
duct by gallstones, alcohol and certain drugs that
cause acinar cell damage, medical procedures
or trauma that damage pancreatic tissue, and
autoimmune diseases (2). In approximately one-
third of cases, the underlying etiology of the
pancreatitis is unknown (idiopathic) (3, 4).Most
acute pancreatitis cases will resolve with sup-
portive care; however, up to 20% of patients will
develop severe tissue damage and will either
succumb tomultiorgan system failure or suffer
from bouts of recurrent disease with markedly
diminished quality of life (2–4). Individuals with
hereditary acute pancreatitis progress to chronic
pancreatitis with amuch higher penetrance and
have a 40 to 55% lifetime risk of developing pan-
creatic cancer (1, 5). Indeed, chronic pancreatitis
promotesmutant Kras-mediated development of
pancreatic cancer in mice (6).
The glycan carbohydrate antigen 19-9 (CA19-9)
is found in the serum of 10 to 30% of pancreatitis
patients and in 75%of pancreatic cancer patients,
as well as in patients with other gastrointestinal
diseases (7–16). CA19-9 elevation is also detected
in pancreatic intraepithelial neoplasms (PanINs),
which are precursors to pancreatic ductal ade-
nocarcinoma (PDAC) (17). CA19-9 [sialyl-Lewisa
(sLea)] is generated by the stepwise addition of
sugar moieties to type I precursor chains present
on proteins and other molecules, culminating in
the a1,4 linkage of fucose toN-acetylglucosamine
(fig. S1A). Fucosyltransferase 3 (FUT3) is the only
enzyme with the ability to add fucose moieties
through an a1,4 linkage and generate CA19-9.
Mice lack this enzyme because Fut3 is a pseu-
dogene in rodents (18, 19).
To facilitate the discovery of PDAC biomarker
candidates, we sought to create amousemodel of
PDAC that recapitulated the elevation of CA19-9
observed in human patients. This model would
enable prioritization of biomarkers that out-
performCA19-9. Furthermore, changes to glyco-
sylation often result in functional consequences.
In this study, we investigated the role of CA19-9
elevation inmouse and organoidmodels of pan-
creatic disease.
Recapitulation of CA19-9 elevation and
regulation in cultured mouse PDAC cells
To express CA19-9 inmouse cells, we transduced
mouse PDAC cells with human FUT3. Expres-
sion of FUT3 alone was insufficient for CA19-9
production but did lead to increased levels of
Lewisx antigens after removal of terminal galac-
tosemoieties present in rodents but not humans
(Fig. 1A). The generation of the related Lewisx
epitopes suggested that reprogramming of the
precursor substrates would be necessary for the
production of CA19-9 in pancreatic ductal cells.
b1,3-galactosyltransferase 5 (b3GALT5) is required
for the production of type I chain precursors (20),
which serve as the precursors for the Lewisa
modification (fig. S1A). Accordingly, expression
of both FUT3 and b3GALT5 inmouse PDAC cells
led to the cell surface expression of CA19-9 at
levels equivalent to those observed in human
cancer cell lines (COLO205, SUIT2) (Fig. 1B and
fig. S1B). Comparable CA19-9 levels were observed
in the blood of mice after orthotopic transplanta-
tion of the CA19-9–expressing mouse and human
cells (fig. S1C).
To determine whether the murine PDAC cell
proteins harboring CA19-9modification are simi-
lar to those in human PDAC cells, CA19-9 protein
carriers were immunoprecipitated (IP) and iden-
tified by mass spectrometry (MS) (fig. S2A and
table S1). These analyses identified knownCA19-9
protein carriers in the FUT3- and b3GALT5-
expressing mouse cells (n = 3; FC1199, FC1242,
FC1245), including CD44, LGALS3BP,MUC1, and
MUC5AC (21–24). The human PDAC cell line,
MiaPaCa-2, is CA19-9 negative, and therefore,
we used it as a control to identify human CA19-9
core proteins in the CA19-9–positive cell lines,
Capan-2, SUIT2, and hM1-2D (fig. S2B and table
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S2). We compared mouse and human CA19-9
protein carriers and found that an average of
72.3% (95% confidence interval 60.3 to 84.3%;
n = 3) of the CA19-9–modified proteins identi-
fied in all three human PDAC cell lines were
also found in the engineered murine PDAC cell
lines. Thus, expression of the human FUT3
and b3GALT5 genes in mouse cells largely re-
capitulates the human CA19-9 carrier profile
(Fig. 1C).
CA19-9 elevation in mice leads to acute
and chronic pancreatitis
We next generated a mouse model with induc-
ible CA19-9 expression to study the effects of
this glycan on pancreatic disease pathogenesis
(fig. S2, C to E). Using PDX1-Cre (C), we restricted
expression of the transgenes to the pancreas,
duodenum, and bile duct. Cre-mediated excision
of a LoxP-flanked stop (LSL) cassette enables
ubiquitous expression of the reverse tetracycline-
controlled transactivator 3 and mKate2 from the
CAGS promoter within the ROSA26 locus (RLSL)
(25). Addition of doxycycline (Dox) to the diet ac-
tivates the reverse tetracycline-controlled trans-
activator, enablingFUT3, b3GALT5, and enhanced
green fluorescent protein (eGFP) expression from
the tetracycline response element promoter in the
COLA1 locus (F) (26). In addition, we excised the
LSL cassette in the R allele to generate animals
with Dox-inducible, whole-body CA19-9 expres-
sion (R;F). Both C;RLSL;F and R;F Dox-treated
mice exhibited histologic signs of pancreatitis,
including interstitial edema, lymphocyte infil-
tration, and collagen deposition (Fig. 2A and fig.
S3, A and B). All other nonpancreatic tissues ap-
peared histologically normal in both Dox-treated
and untreated models and their littermate con-
trols (figs. S4 and S5). Themice progressed from
acute to chronic pancreatitis after 28 days of
Dox treatment as demonstrated by the clinical
histopathological hallmarks of acinar atrophy,
accumulation of metaplastic ductal lesions, and
persistent fibroinflammatory disease (figs. S3, A
and B, and S6, A and B) (27). Pancreatitis was
highly penetrant in both models (Fig. 2B and fig.
S6, C and D).
Both mouse models demonstrated elevated
serum levels of the pancreatic enzymes amylase
and lipase within 24 hours of Dox treatment, but
no changes were observed in untreatedmice and
littermate controls (Fig. 2C and fig. S6, C and D).
Patients with acute pancreatitis have elevated
serum levels of amylase and lipase, but in the
chronic phase of pancreatitis, the levels of these
enzymes either normalize or decrease even fur-
ther.We found in ourmousemodels that the levels
of amylase and lipase began to normalize after
4 weeks of Dox treatment, but both C;RLSL;F
and R;F mice still exhibited histologic signs
of chronic pancreatitis. Expression of eGFP and
CA19-9 was detected in the pancreas after Dox
treatment of C;RLSL;F mice and R;F mice, but
they were not detected in untreated or control
littermates (Fig. 2A and figs. S3C, S7, and S8). In
both mouse models, CA19-9 was predominantly
expressed in intralobular, intercalated, andmeta-
plastic pancreatic ducts as well as in islet cells
(Fig. 2A and figs. S3C, S7, and S8). Both models
exhibited elevatedCA19-9 levels in the circulation
(Fig. 2D and fig. S6, C and D). Secreted CA19-9
was also observed coating eGFP-negative endo-
thelial cells as well as fibroblasts (figs. S7B and
S8). E-selectin is an endogenous receptor of
CA19-9 expressed by endothelial cells (28, 29)
and may explain the accumulation of CA19-9
within the vasculature. Despite recombination
in the acinar compartment, acinar cells were
rarely observed to be CA19-9 positive. R;F mice
exhibited Dox-dependent expression of CA19-9
and eGFP in all tissues examined, whereas in
C;RLSL;F mice, expression was limited to the
pancreas, duodenum, and gall bladder (Fig. 2A
and figs. S3, C to G, and S7 to S11).
We next sought to determine the prevalence
of CA19-9 elevation in human pancreatic dis-
ease and to compare the CA19-9 tissue expres-
sion pattern observed in human patients and
the CA19-9 genetically engineeredmousemodels.
We therefore evaluated CA19-9 levels and expres-
sion patterns in patients, including specimens
of pancreatic cancer and adjacent normal tissue
(n = 72) as well as surgically resected chronic
pancreatitis samples (n = 44) (figs. S12 and S13).
CA19-9 was expressed at low levels in normal
homeostatic pancreatic ducts and at elevated
levels in adjacent reactive ducts that consist of
atypical, benign pancreatic ducts that occur
even in the absence of substantial inflammation
(fig. S12A), preinvasive carcinomas (PanIN-1A
and PanIN-1B), and invasive PDAC specimens
(fig. S12, B to D) (17). In chronic pancreatitis
specimens, CA19-9 was expressed at high levels
in the reactive and metaplastic ducts with more
sporadic expression in the centroacinar and aci-
nar compartments (fig. S13, A and B, and table
S3). Elevated levels of CA19-9 were detected in
the serum of 20% of the chronic pancreatitis
patients we examined, whereas more than 93%
of these patients exhibited local elevation of
CA19-9 in the resected pancreatic specimens
by immunohistochemistry (IHC) (n = 44) (fig.
S13, C and D). Together, these data indicate that
CA19-9 elevation is a common feature of chronic
pancreatitis and that the CA19-9 expression pat-
tern is similar between the CA19-9mousemodels
and human patients.
Patients with severe acute or chronic pan-
creatitis often also exhibit weight loss (30, 31).
Therefore, we assessed the health and weight
of both mouse models. Whereas most C;RLSL;F
mice maintained their overall health status
after Dox treatment, Dox-treated R;F mice ex-
hibited significant body weight loss (fig. S14A).
In severe cases, the weight loss exceeded 20%,
and euthanasiawas required. Theweight losswas
not due to pathology of the stomach, duodenum,
or colon and was not associated with an auto-
immune reaction, induction of endoplasmic re-
ticulum stress in the pancreas, or loss of glycemic
control (32) (fig. S14, B to D). Pancreatic exocrine
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Fig. 1. FUT3 with b3GALT5 expression enables CA19-9 production in engineered mouse pan-
creatic cancer cells. (A) Ectopic FUT3 induces Lewisx (Lex) but not CA19-9–sLea expression in mouse
PDAC cells by flow cytometric analysis. The Lex- and CA19-9–sLea—positive human cell line COLO205
and Lex- and CA19-9–sLea—negative parental KPC cell lines are shown. FITC, fluorescein isothio-
cyanate; FSC-A, forward scatter–area; AF568, Alexafluor 568. (B) CA19-9 flow cytometry of mouse
PDAC cells stably and constitutively expressing FUT3 with b3GALT5 (FB) compared with the isotype
control antibody. (C) Overlap between CA19-9 protein carriers identified in three out of three human
PDAC cell lines (n = 926) with three independent mouse PDAC cell lines expressing FUT3 and b3GALT5.
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insufficiency is often observed in cases of chronic
pancreatitis and can cause severe weight loss
and destruction of the acinar compartment in
patients (31). R;F mice exhibited a significant
Dox-dependent decrease in pancreatic mass,
whereas no change was observed in C;RLSL;F
mice and littermate controls after Dox treatment
(fig. S14E). In addition, we observed a signifi-
cant and sustained increase in steatorrhea in
R;F mice, whereas C;RLSL;F mice exhibited a
transient increase in fecal triglycerides that
normalized within 4 weeks of Dox treatment
(fig. S14F). The pancreatic atrophy and steator-
rhea in R;F mice was accompanied by a sig-
nificant reduction of fecal elastase in R;F mice
within the first week of Dox treatment (fig. S14G).
Together, these data indicate that R;Fmice suffer
from pancreatic atrophy and exocrine insuffi-
ciency. Both the increased penetrance of CA19-
9 expression in the Cre-independent R;Fmodel
and expression of CA19-9 in other tissues may
contribute to the severe pancreatitis observed
in this model.
Human pancreatitis is associated with an in-
flux of macrophages to the pancreas during the
acute phase of the disease; after progression to a
chronic condition, T and B cells also infiltrate
the pancreas (33, 34). To determine whether
this aspect of human pancreatitis is also found
in mouse models of pancreatitis, we examined
the immune infiltrate in C;RLSL;F mice and the
established ceruleinmodel of acute pancreatitis.
Flow cytometry revealed an influx of immune
cells into the pancreas, including recruitment
of inflammatory monocytes and macrophages,
after induction of pancreatitis (Fig. 2E and figs.
S15 and S16A). This result was confirmed by IHC
(fig. S16B). Neither model showed significant re-
cruitment of T or B cells at the acute pancreatitis
time points examined by flow cytometry (1 to
3 days) (fig. S15). At the chronic phase of pan-
creatitis, both R;F and C;RLSL;F models contained
intrapancreatic T and B cells as indicated by IHC
(fig. S17). Therefore, both the CA19-9 and cerulein
mouse models of pancreatitis exhibited immune
infiltrates similar to those found in patients with
pancreatitis.
Pancreatic cell proliferation is a common fea-
ture of human pancreatitis (35). Cerulein-treated
mice exhibited an elevation inKi67-positive nuclei
in the infiltrating immune cells as well as in the
ductal and acinar compartments. Similarly, both
R;F and C;RLSL;F mice exhibited increased Ki67-
positive nuclei in the immune, acinar, and ductal
compartments in the acute phases of pancrea-
titis, which gradually diminished as the mice
progressed to chronic pancreatitis (fig. S18, A
to E). Increased ethynyl deoxyuridine (EdU) in-
corporation was also observed in the pancreas,
including elevation in the immune, ductal, and
Engle et al., Science 364, 1156–1162 (2019) 21 June 2019 3 of 7
Fig. 2. CA19-9 expression promotes pancreatitis in mice. (A) Histologic
evaluation of C;RLSL;F mice by hematoxylin and eosin (HE) staining, Masson’s
trichrome staining (MT) (blue indicates collagen deposition), and CA19-9
expression (open arrow, CA19-9+ duct; closed arrow, CA19-9+ islet) by IHC
after treatment with Dox. Scale bars = 50 mm. (B) Quantification of the
percentage of pancreatic area exhibiting histologic signs of pancreatitis after
treatment of C;RLSL;F mice with Dox. (C) Circulating levels (U/L) of the
pancreatic enzymes amylase and lipase in C;RLSL;F mice after treatment with
Dox (days). The dotted line indicates the threshold elevation required for
the diagnosis of pancreatitis. The dashed line indicates the maximum level of
detection possible for amylase. (D) The circulating level of CA19-9 (U/ml)
after treatment of C;RLSL;Fmice with Dox.Values that exceed 37 U/ml (dotted
line) are elevated. (E) Immune cell infiltration evaluated by flow cytometry
in mice treated with phosphate-buffered saline (PBS) or cerulein (Ceru) for
2 days followed by a 1- or 3-day recovery period (C57Bl/6j; n = 5, 5, and
5, respectively) and C;RLSL;F mice treated with Dox (n = 4, 4, and 6,
respectively) compared with “genetically negative” controls (GN) (n = 3
and 3, respectively). Outlier analysis using Grubb’s method identified one data
point (triangle symbol, GN, 3 days of Dox) as an outlier. (F) EdU incorporation
in the pancreas was evaluated by flow cytometry in C;RLSL;F mice (n = 3, 3,
and 4, respectively) and littermate GNs (n = 3 and 2, respectively) after
treatment with Dox. Middle horizontal red lines represent the mean, and error
bars represent the standard deviation; each data point represents a
measurement from an individual mouse. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 for multiple comparisons using Holm-Sidak’s procedure
following a one-way analysis of variance.
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fibroblast compartments (Fig. 2F and fig. S18F).
Together, these data demonstrate that CA19-9–
mediated pancreatitis in mice bears similarity
to the human disease.
CA19-9 expression results in
hyperactivation of epidermal growth
factor receptor signaling
To identify the molecular mechanisms underly-
ing the pancreatitis phenotype observed in mice,
we focused our studies on the C;RLSL;F model.
Other researchers have established that epider-
mal growth factor receptor (EGFR) signaling is
necessary and sufficient for the induction of
pancreatitis and is important for the initiation of
pancreatic cancer in mice (36, 37). Accordingly,
we found that the levels of tyrosine phosphoryl-
ated and activated EGFR were prominently ele-
vated in the pancreatic ducts of C;RLSL;F mice
after Dox treatment (Fig. 3A). To identify the al-
terations in cell signaling pathways that occur in
direct response to CA19-9 expression, we isolated
pancreatic ductal organoids from C;RLSL;F mice
(38). RNA-sequencing analyses of the C;RLSL;F
organoids after induction of CA19-9 expression
revealed the expected changes in transgene ex-
pression (fig. S19, A to F, and table S4). FUT3
and b3GALT5 expression levels were compara-
ble between mouse and human ductal organo-
ids (fig. S19D) (39).
Gene set enrichment analysis identified sig-
nificant changes to 21 pathways in the hallmarks
of cancer gene sets and 64 pathways annotated
in the KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathway gene sets (Fig. 3B and table
S4). CA19-9 expression triggered a reduction in
expression of genes associated with the unfolded
protein response and an increase in expression
of genes associated with chemokine, hedgehog,
Janus kinase–signal transducers and activators of
transcription, and transforming growth factor–b
signaling. The latter genes may participate in
the activation of the fibroblast compartment
and recruitment of the immune infiltrate (e.g.,
interleukin-1a, colony-stimulating factor 1, tumor
necrosis factor). We further explored enrichment
of the extracellular matrix (ECM)–receptor in-
teraction, ERBB, phosphatidylinositol 3-kinase
(PI3K), and AKT signaling pathways (Fig. 3B).
CA19-9 expression in C;RLSL;F organoids resulted
in elevated EGFR phosphorylation (Y1068 and
Y1148) and decreased total EGFR, indicating
greater flux through this pathway (40) (Fig. 3C
and fig. S20, A, B, and E to G). The increase in
phosphorylated EGFR was accompanied by
increased phosphorylation of focal adhesion
kinase (FAK) (Y397), AKT, and extracellular
signal–regulated kinase 1 and 2 (ERK1/2) (Fig.
3C and fig. S20F). Coincident FAK and EGFR
activation through integrin-mediated interaction
with the ECM has been previously reported in
three-dimensional but not monolayer culture
models (41, 42). EGFR stimulation by EGF was
more rapid and robust in organoids that were
previously cultured in EGF-free conditions, but
EGF stimulation did not induce FAK phospho-
rylation (fig. S20, C and D). Although the al-
terations of phosphorylated EGFR, total EGFR,
and their ratio were consistent among biological
replicates, no consistent changes to total or phos-
phorylated S6, HER2, and p65 were observed
(fig. S20, A and B). These findings were inde-
pendent of the inclusion of murine EGF in the
media of the cultures (fig. S20E), and the level
of phospho- and total EGFR and downstream
effector induction exceeded the increase ob-
served after treatment with additional EGF
(fig. S20, B to D).
The glycosylation state of EGFR has been
reported to affect its ability to activate and to
respond to targeted kinase inhibitors (43, 44).
Accordingly, we examined whether EGFR was
modified by CA19-9 in mouse organoids, but
this was not detected (fig. S20H). To investigate
whether the CA19-9–dependent activation of
EGFR was due to a soluble ligand, we evaluated
conditioned medium from CA19-9–expressing
organoids and found that it stimulated EGFR
phosphorylation in control murine ductal organ-
oids (Fig. 3, D to F). This activity was attenuated
by the addition of EGFR-Fc (EGF trap), further
supporting the presence of one or more EGFR
ligands (Fig. 3, D and F). Addition of a mono-
clonal antibody to CA19-9 (NS19-9) was also
sufficient to block EGFR phosphorylation in
C;RLSL;F organoids (Fig. 3, D and G). These
findings suggested the presence of a CA19-9–
modified, secreted EGFR ligand.
EGFR complexes from C;RLSL;F organoid
lysates were identified by IP-MS (Fig. 4A and
table S5). We observed elevated levels of endog-
enous fibulin-3 [Efemp1 (FBLN3)] by IP-MS in
C;RLSL;F, but not control organoids, after Dox
treatment (Fig. 4A). FBLN3, a secreted matri-
cellular glycoproteinwith five EGF-like domains,
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Fig. 3. CA19-9 expression activates EGFR signaling. (A) Representative phosphorylated EGFR IHC
in C;RLSL;Fmice that were treated for 0 (n = 4) or 3 (n = 5) days with Dox. Insets are higher magnification
of pancreatic ducts. Scale bars = 50 mm. (B) Gene Set Enrichment Analysis of C;RLSL;F organoids
identified enrichment in PI3K/AKT/mTOR and ECM-receptor signaling and downstream effector path-
ways. FDR, false discovery rate; NES, normalized enrichment score. (C) C;RLSL;Forganoids (n=3biological
replicates) and GN organoids (n = 2 biological replicates) were evaluated by immunoblot for the activation
of signaling pathways after treatment with Dox. Blots are representative of three technical replicates,
three biological replicates of C;RLSL;F organoids, and two biological replicates of GN organoids. p,
phosphorylated; t, total. (D) Quantification of changes to the ratio of phosphorylated to total protein is
shown for Fig. 3, E to G. (E and F) Organoids from GN littermates were incubated with conditioned
media (CM) from C;RLSL;F organoids with or without previous Dox treatment (24 hours) in the presence
or absence of Fc control or EGFR-conjugated Fc and evaluated by immunoblot. (G) C;RLSL;F organoids
(n = 3 biological replicates) were treated with Dox (hours) in the presence of isotype control
(MOPC-21) or CA19-9–blocking monoclonal antibody (NS19-9) and evaluated by immunoblot.
Blots are representative of two technical and three biological replicates.
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has been proposed to be a ligand for EGFR (45).
Furthermore, we performed CA19-9 IP-MS from
the conditionedmedia using twodifferent CA19-9
monoclonal antibody clones and identifiedFBLN3
as a secreted, CA19-9–modified protein (Fig. 4B,
fig. S21A, and table S6).
To confirm the glycosylation status of FBLN3,
we coexpressed FLAG epitope–tagged FBLN3 in
the presence or absence of FUT3 and b3GALT5
inmouse PDAC cells and detected CA19-9modi-
fication of secreted FBLN3 (fig. S21B). The mRNA
expression of fibulin familymembers and EGFR
ligands did not change after Dox treatment of
C;RLSL;F organoids (fig. S21C). Furthermore, the
total protein levels of FBLN3 were unchanged
after CA19-9 expression in organoid-conditioned
media and in mouse plasma in vivo (fig. S21D).
Secreted FLAG-FBLN3 isolated by immunopre-
cipitation coprecipitated with EGFR in PDAC
cell lysates, consistent with an association of
FBLN3 with EGFR (Fig. 4C). Because the asso-
ciation of ectopic FLAG-FBLN3with EGFR in cell
lysates occurs irrespective of its CA19-9 glycosyl-
ation status, the finding that the glycosylation
status of endogenous FBLN3 increases associ-
ation with EGFR may reflect the interaction of
sLea–modified FBLN3 with additional extracel-
lular proteins. To determine whether FBLN3 is
necessary for the activation of the EGFRpathway
after CA19-9 expression, multiple FBLN3-blocking
antibodies and short-hairpinRNA (shRNA) vectors
were utilized and shown to prevent EGFR phos-
phorylation and the activation of downstream
effector pathways in C;RLSL;F organoids (Fig. 4,
D and E, and fig. S21, E and F).
CA19-9 as a therapeutic target
in pancreatitis
We designed a Dox pulse-chase approach to
determine if CA19-9 expression is required to
maintain pancreatitis. CA19-9–mediated pancre-
atitis was completely reversed in C;RLSL;F mice
after a 3-dayDox pulse and 4-day recovery period
(fig. S22, A to C). Partial resolution of chronic
pancreatitis in the C;RLSL;F model (28-day Dox
treatment) was also observed after a 14-day re-
covery period (fig. S22, D and E). In a preventive
setting of acute pancreatitis, two antibodies di-
rected against CA19-9 both reduced immune in-
filtration, ductal metaplasia, and fibrosis in vivo
(Fig. 5A and fig. S22, F and G). In addition,
decreased release of amylase and lipase into
the circulation and reduced hyperactivation of
EGFR were observed (Fig. 5, B and C, and fig.
S22, H and I). In an intervention setting of
existing acute pancreatitis, we found that two
forms of 5B1 significantly reduced the secretion
of amylase into the circulation with modest
normalization of the pancreatic histology (fig.
S22, J to L). CA19-9 antibody treatment of exist-
ing acute pancreatitis also reduced the levels of
phosphorylated EGFR in both the ductal and
acinar compartments and decreased recruit-
ment of macrophages (fig. S22, M and N). These
data suggest that CA19-9 plays a role in disease
pathogenesis andmaintenance and that CA19-9–
targeted therapy may warrant further therapeu-
tic exploration.
Inhibition of EGFR in vivo by using erlotinib
was not as effective as CA19-9 antibody blockade
to mitigate pancreatitis induction in mice (fig.
S23, A to F). Indeed, erlotinib treatment of CA19-
9–expressing mice caused severe weight loss,
necessitating euthanasia. These effects were
unrelated to erlotinib toxicity in control mice.
Although serum levels of amylase and lipase
decreased in erlotinib-treated animals, pancre-
atic atrophy and acinar cell vacuolization were
observed, suggesting that the weight loss were
due to increased pancreatitis severity and result-
ing exocrine insufficiency (fig. S23, B and C).
Erlotinib treatment also incompletely blocked
phospho-EGFR levels in vivo (fig. S22D). Acinar-
ductalmetaplasia (ADM) can bedetectedby SOX9
IHC (36) and occurred after 7 days of Dox treat-
ment in the C;RLSL;Fmodel (fig. S22E). Although
ADMwas less apparent in the erlotinib-treated
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Fig. 4. CA19-9–modified fibulin-3 activates EGFR. (A) IP-MS of EGFR complexes from C;RLSL;F
(n = 3) and GN organoid (n = 2) whole-cell lysates after Dox administration (8 hours). (B) CA19-9 protein
carrier IP-MS analysis of fibulin-3 from conditioned media from C;RLSL;F organoids treated with Dox
for 0 to 8 hours (n = 3) relative to untreated and treated GN organoids (n = 1) using 5B1 CA19-9 antibody
clone. (C) Immunoblot of IP fibulin-3 (FLAG) after incubation with lysates from pancreatic cancer
cells lacking FLAG-FBLN3 expression. ISO, isotype control antibody. (D) C;RLSL;F organoids (n = 3)
treated with Dox in the presence of MOPC-21 or three independent fibulin-3 antibodies (FBLN3 Ab) and
evaluated by immunoblot. Changes to the ratio of phosphorylated to total protein levels are included.
mAb, monoclonal antibody; pAb, polyclonal antibody. (E) Organoids transduced with hairpins to GFP or
to FBLN3 were immunoblotted after Dox treatment. Changes to the ratio of phosphorylated to total
protein levels are included. Middle horizontal red lines represent the mean, and error bars represent the
standard deviation. *P < 0.05 by unpaired, two-tailed t test.
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C;RLSL;F mice (fig. S22F), lymphocyte infiltra-
tion and fibrosis remained unaffected. CA19-9
sequestration is unlikely to interfere with ADM
survival mechanisms in the acinar compart-
ment, given that these cells are largely CA19-9
negative (46). Therefore, EGFR kinase inhibi-
tion alone cannot substitute for CA19-9 blockade
and may be a harmful therapy in the setting of
pancreatitis.
Pancreatic tumorigenesis is accelerated
by CA19-9–mediated pancreatitis
To determine whether CA19-9 expression pro-
moted PDAC,we intercrossed the C;RLSL;F alleles
with the conditionalKrasLSL-G12D allele (K;C;RLSL;F)
(fig. S24A) (47, 48). CA19-9 expression signifi-
cantly accelerated pancreatic cancer lethality
relative to untreated mice and control littermates
(Fig. 6A). When treated with Dox, K;C;RLSL;F
mice rapidly succumbed to primary and meta-
static pancreatic cancer with a median survival
of 202 days relative to 460 days in the K;C
control cohort and 420 days in the untreated
K;C;RLSL;F cohort. The primary tumors were
anaplastic with glandular features (Fig. 6B).
Widespread metastases were observed in the
peritoneum, diaphragm, liver, and lung in mul-
tiple Dox-treated K;C;RLSL;F mice. To better
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Fig. 5. CA19-9 as a therapeutic target for the
treatment of pancreatitis. (A) HE staining of
representative areas from C;RLSL;Fmice after
treatment with human isotype control (hIgG1;
n = 5) or the CA19-9 antibody clone 5B1 (n = 5) for
8 days and Dox for the last 7 days. Scale bars =
100 mm. (B) Serum amylase and lipase levels
in C;RLSL;Fmice treated with 5B1 or isotype
control. (C) Phospho-EGFR IHC on representative
mice treated with either isotype or 5B1 as
described in Fig. 5A. Scale bars = 50 mm. Middle
horizontal red lines represent the mean, and
error bars represent the standard deviation; each
data point represents a measurement from an
individual mouse. P value was determined by
using an unpaired, parametric, two-tailed t test.
*P < 0.05, **P < 0.01.
Fig. 6. CA19-9 promotes rapid
and aggressive pancreatic
tumorigenesis. (A) Survival curve
for untreated (eight deaths out
of 19 mice) and Dox-treated
K;C;RLSL:F mice (14 deaths out of
19 mice) and K;C GNs (13 deaths
out of 34 mice). The P value was
determined by a log-rank Mantel-Cox
test. (B) Representative histology
of pancreatic tumors and metastatic
lesions from Dox-treated K;C;RLSL:F
mice. Scale bars = 200 mm.
(C) Representative histology
(scale bars = 100 mm), (D) CA19-9
IHC (scale bars = 100 mm), and
(E) pEGFR IHC (scale bars =
50 mm) of the pancreata from
K;C and K;C;RLSL:F mice after 2 to
4 weeks of Dox treatment.
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understand the role of CA19-9 in PDAC initia-
tion, we examined the effect of short-termCA19-9
expression onpancreatic transformation.Whereas
littermate controls exhibited the expected low
burden ofmPanIN-1A lesions, CA19-9–expressing
animals harbored a high penetrance of cystic
and fibroinflammatory disease with abundant
mPanIN-1B and occasional mPanIN-2 lesions
after 2 weeks of Dox (Fig. 6C) and increased mac-
rophage infiltration relative to the K;C control
cohort (fig. S24, B and C). After 4 weeks of Dox,
cystic papillary neoplasia and invasive carcinoma
could be detected (Fig. 6C). CA19-9 expression
was elevated in normal, benign-reactive, and
metaplastic ducts as well as in mPanIN and
PDAC lesions in K;C;RLSL;F mice, similar to the
human expression pattern (Fig. 6D and fig. S12).
Equivalent levels of CA19-9 were also observed in
human PDAC andmouse K;C;RLSL;F organoids
(fig. S24D). Phosphorylated EGFR (Fig. 6E) was
detected at high levels in Dox-treated K;C;RLSL;F
mice, whereas CA19-9–negative K;C mice exhib-
ited low to negative levels of phospho-EGFR.
Discussion
CA19-9 is expressed at low levels in the normal
ducts of the pancreas but becomes elevated in
benign-reactive,metaplastic, andmalignant ducts
in humans. It is conceivable that the degree of
CA19-9 elevation could impart a way to control
the degree of fibroinflammatory response in both
pancreatitis and PDAC. Mice retain the ability to
respond to elevations in CA19-9 despite the fact
that they do not normally express this glycan.
The ability of mice to respond to CA19-9 eleva-
tion may be due to the existence of similar regu-
latory mechanisms for related Lewis antigens
(e.g., sialyl-Lewisx) that are involved in similar
processes in other organs and have also been
shown to substitute for CA19-9 in individuals
lacking this glycan (49).
Patients with pancreatitis have an elevated
risk (2.7- to 16.5-fold) of developing PDAC, and
individuals with hereditary pancreatitis have a
40 to 55% lifetime risk of developing pancreatic
cancer (1, 5). Therapeutic options for pancreatitis
patients are now focused on treating the symp-
toms, and little can be done to facilitate the reso-
lution of idiopathic pancreatitis or to prevent its
recurrence, highlighting the need for new treat-
ments. Prophylactic intervention could also be
beneficial in the setting of recurrent or hereditary
pancreatitis and after certain routine procedures
for which pancreatitis is a common outcome. For
example, 3.5% of the >700,000 patients under-
going endoscopic retrograde cholangiopancrea-
tography each year in the United States will
develop pancreatitis (50, 51); several risk fac-
tors can be used to identify patients at elevated
risk for endoscopic retrograde cholangiopan-
creatography–associated pancreatitis (40%) (52).
Fully human CA19-9 antibodies have passed
phase 1A clinical trials for positron emission
tomography imaging of pancreatic cancer (53).
This could potentially facilitate rapid translation
of CA19-9–targeted therapy to the clinic for the
treatment of pancreatitis.
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